Literature DB >> 9129103

Long-lasting antibodies detected by a trans-sialidase inhibition assay of sera from parasite-free, serologically cured chagasic patients.

M S Leguizamón1, G Russomando, A Luquetti, A Rassi, M Almirón, S M González-Cappa, A C Frasch, O Campetella.   

Abstract

A test based on the inhibition by antibodies of the trans-sialidase was used to analyze infection by Trypanosoma cruzi, the agent of Chagas' disease. Sera collected during the longitudinal follow-up of benznidazole-treated acutely and congenitally infected patients became negative for T. cruzi as determined by tests presently used to assess cure; however, the sera remained positive for T. cruzi by the trans-sialidase inhibition assay (TIA) up to 14 years after treatment. Therefore, TIA is a highly sensitive marker for previous T. cruzi infection.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9129103     DOI： 10.1086/593697

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  13 in total

1.  trans-sialidase inhibition assay, a highly sensitive and specific diagnostic test for Chagas' disease.

Authors:  A S Buchovsky; O Campetella; G Russomando; L Franco; R Oddone; N Candia; A Luquetti; S M Gonzalez Cappa; M S Leguizamon
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

2.  Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.

Authors:  T A Pitcovsky; J Mucci; P Alvarez; M S Leguizamón; O Burrone; P M Alzari; O Campetella
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

3.  Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.

Authors:  Vera Lucia Pereira-Chioccola; Abilio Augusto Fragata-Filho; Antonio Marcos de Apparecida Levy; Mauricio M Rodrigues; Sergio Schenkman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

4.  Continuous nonradioactive method for screening trypanosomal trans-sialidase activity and its inhibitors.

Authors:  Paula A Sartor; Rosalía Agusti; Maria S Leguizamón; Oscar Campetella; Rosa M de Lederkremer
Journal:  Glycobiology       Date:  2010-04-07       Impact factor: 4.313

5.  The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents.

Authors:  María Virginia Tribulatti; Juan Mucci; Nico Van Rooijen; María Susana Leguizamón; Oscar Campetella
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

6.  Thymocyte depletion in Trypanosoma cruzi infection is mediated by trans-sialidase-induced apoptosis on nurse cells complex.

Authors:  Juan Mucci; Alejandra Hidalgo; Esteban Mocetti; Pablo F Argibay; M Susana Leguizamon; Oscar Campetella
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

7.  Use of trans-Sialidase inhibition assay in a population serologically negative for Trypanosoma cruzi but at a high risk of infection.

Authors:  M S Leguizamón; G Russomando; A Rojas de Arias; M Samudio; M Cabral; S M González-Cappa; A C Frasch; O Campetella
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

8.  Estimation of sensitivity and specificity of several Trypanosoma cruzi antibody assays in blood donors in Argentina.

Authors:  Mirta C Remesar; Cecilia Gamba; Ivana F Colaianni; Mónica Puppo; Paula A Sartor; Edward L Murphy; Torsten B Neilands; María A Ridolfi; M Susana Leguizamón; Silvina Kuperman; Ana E Del Pozo
Journal:  Transfusion       Date:  2009-11       Impact factor: 3.157

Review 9.  Parasite-host glycan interactions during Trypanosoma cruzi infection: trans-Sialidase rides the show.

Authors:  Oscar Campetella; Carlos A Buscaglia; Juan Mucci; María Susana Leguizamón
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-20       Impact factor: 5.187

10.  Trypanosoma cruzi in persons without serologic evidence of disease, Argentina.

Authors:  Oscar A Salomone; Ana L Basquiera; Adela Sembaj; Ana M Aguerri; María E Reyes; Mirtha Omelianuk; Ruth A Fernández; Julio Enders; Atilio Palma; José Moreno Barral; Roberto J Madoery
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.